MeiraGTx/$MGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
372
ISIN
KYG596651029
Website
MeiraGTx Metrics
BasicAdvanced
$521M
-
-$2.27
1.31
-
Price and volume
Market cap
$521M
Beta
1.31
52-week high
$8.75
52-week low
$3.85
Average daily volume
536K
Financial strength
Current ratio
1.525
Quick ratio
1.37
Long term debt to equity
234.391
Total debt to equity
244.352
Interest coverage (TTM)
-12.17%
Profitability
EBITDA (TTM)
-146.402
Gross margin (TTM)
27.06%
Net profit margin (TTM)
-484.90%
Operating margin (TTM)
-460.87%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-37.28%
Return on equity (TTM)
-216.14%
Valuation
Price to revenue (TTM)
13.814
Price to book
15.55
Price to tangible book (TTM)
15.92
Price to free cash flow (TTM)
-4.351
Free cash flow yield (TTM)
-22.99%
Free cash flow per share (TTM)
-148.94%
Growth
Revenue change (TTM)
203.23%
Earnings per share change (TTM)
84.70%
3-year revenue growth (CAGR)
-3.78%
3-year earnings per share growth (CAGR)
5.00%
What the Analysts think about MeiraGTx
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Bulls say / Bears say
MeiraGTx entered into a strategic collaboration with Hologen AI, receiving a $200 million upfront payment and forming a joint venture with an additional $230 million committed to expedite Phase 3 development of AAV-GAD for Parkinson’s disease. (MeiraGTx News Releases)
The company reported a significant increase in revenue, reaching $33.28 million in 2024, a 137.42% rise from the previous year's $14.02 million, indicating strong financial growth. (Stock Analysis)
MeiraGTx received Rare Pediatric Disease Designation from the FDA for AAV8-RK-RetGC, enhancing its pipeline's value and potential market exclusivity. (MeiraGTx News Releases)
Despite increased revenue, MeiraGTx reported a net loss of $147.79 million in 2024, a 75.9% increase from 2023, raising concerns about profitability. (Stock Analysis)
The company's debt-to-equity ratio stands at 108%, indicating high leverage and potential financial risk. (Simply Wall St)
MeiraGTx's Altman Z-score is -2.10, placing it in the distress zone and suggesting a higher risk of bankruptcy within the next two years. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MeiraGTx Financial Performance
Revenues and expenses
MeiraGTx Earnings Performance
Company profitability
MeiraGTx News
AllArticlesVideos
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewsWire·1 month ago
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
GlobeNewsWire·1 month ago
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $521M as of June 20, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of June 20, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.